Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613)
Hong Kong
· Delayed Price · Currency is HKD 7.38
+0.04 (0.54%)
Apr 29, 2026, 4:08 PM HKT
HKG:3613 Income Statement
Financials in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 1,513 | 1,612 | 1,525 | 1,731 | 1,556 | Upgrade
|
| Revenue Growth (YoY) | -6.10% | 5.68% | -11.91% | 11.24% | 18.31% | Upgrade
|
| Cost of Revenue | 587.78 | 546.32 | 477.7 | 580.96 | 436.54 | Upgrade
|
| Gross Profit | 925.58 | 1,065 | 1,047 | 1,150 | 1,120 | Upgrade
|
| Selling, General & Admin | 390.41 | 492 | 410.29 | 341.68 | 341.68 | Upgrade
|
| Other Operating Expenses | -2.42 | -2.68 | -8.14 | -2.51 | -1.71 | Upgrade
|
| Operating Expenses | 449.58 | 491.27 | 423.33 | 345.65 | 347.49 | Upgrade
|
| Operating Income | 476 | 574.06 | 623.91 | 804.49 | 772.13 | Upgrade
|
| Interest Expense | -5.66 | -6.48 | -5.98 | -4.66 | -4.71 | Upgrade
|
| Interest & Investment Income | 47.04 | 57.67 | 73.12 | 20.59 | 4.38 | Upgrade
|
| Earnings From Equity Investments | -8.73 | 2.06 | -3.26 | -1.54 | 0.26 | Upgrade
|
| EBT Excluding Unusual Items | 508.65 | 627.3 | 687.79 | 818.88 | 772.06 | Upgrade
|
| Gain (Loss) on Sale of Investments | -4.89 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.93 | 2.47 | - | - | - | Upgrade
|
| Other Unusual Items | - | - | - | 7.09 | 6.33 | Upgrade
|
| Pretax Income | 504.69 | 629.77 | 687.79 | 825.96 | 778.39 | Upgrade
|
| Income Tax Expense | 87.83 | 100.61 | 97.2 | 134.67 | 126.85 | Upgrade
|
| Earnings From Continuing Operations | 416.86 | 529.17 | 590.59 | 691.29 | 651.54 | Upgrade
|
| Minority Interest in Earnings | -19.64 | -28.89 | -50.19 | -45.42 | -43.71 | Upgrade
|
| Net Income | 397.22 | 500.28 | 540.39 | 645.88 | 607.84 | Upgrade
|
| Net Income to Common | 397.22 | 500.28 | 540.39 | 645.88 | 607.84 | Upgrade
|
| Net Income Growth | -20.60% | -7.42% | -16.33% | 6.26% | 12.05% | Upgrade
|
| Shares Outstanding (Basic) | 837 | 837 | 837 | 837 | 837 | Upgrade
|
| Shares Outstanding (Diluted) | 837 | 837 | 837 | 837 | 837 | Upgrade
|
| EPS (Basic) | 0.47 | 0.60 | 0.65 | 0.77 | 0.73 | Upgrade
|
| EPS (Diluted) | 0.47 | 0.60 | 0.65 | 0.77 | 0.73 | Upgrade
|
| EPS Growth | -20.60% | -7.42% | -16.33% | 6.26% | 12.05% | Upgrade
|
| Free Cash Flow | - | -260.42 | 438.97 | 508.94 | 753.74 | Upgrade
|
| Free Cash Flow Per Share | - | -0.31 | 0.52 | 0.61 | 0.90 | Upgrade
|
| Dividend Per Share | 0.370 | 0.350 | 0.330 | 0.330 | 0.280 | Upgrade
|
| Dividend Growth | 5.71% | 6.06% | - | 17.86% | 16.67% | Upgrade
|
| Gross Margin | 61.16% | 66.10% | 68.67% | 66.44% | 71.95% | Upgrade
|
| Operating Margin | 31.45% | 35.62% | 40.91% | 46.47% | 49.62% | Upgrade
|
| Profit Margin | 26.25% | 31.04% | 35.44% | 37.31% | 39.06% | Upgrade
|
| Free Cash Flow Margin | - | -16.16% | 28.79% | 29.40% | 48.44% | Upgrade
|
| EBITDA | 494.82 | 592.88 | 640.57 | 818.84 | 786.5 | Upgrade
|
| EBITDA Margin | 32.70% | 36.79% | 42.01% | 47.30% | 50.54% | Upgrade
|
| D&A For EBITDA | 18.82 | 18.82 | 16.66 | 14.35 | 14.37 | Upgrade
|
| EBIT | 476 | 574.06 | 623.91 | 804.49 | 772.13 | Upgrade
|
| EBIT Margin | 31.45% | 35.62% | 40.91% | 46.47% | 49.62% | Upgrade
|
| Effective Tax Rate | 17.40% | 15.97% | 14.13% | 16.30% | 16.30% | Upgrade
|
| Advertising Expenses | 20.75 | 112.15 | 47.39 | 19.18 | 23.58 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.